ScripModerna appears to have a pathway to approval for its investigational influenza/COVID-19 combination vaccine mRNA-1083 now that it reported positive Phase III efficacy data on June 30 for mRNA-1010, a
ScripThe number of competitive drug candidates transferring from Chinese research and development pipelines to US-based biopharmaceutical company portfolios has grown significantly during the first half of
Pink SheetJuly is inextricably linked with Independence Day in the US, but the calendar of applications that are up for Food and Drug Administration actions in July 2025 is notable for the number of novel candi
ScripBioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed. A Very German Transaction BioNTech’s acq